fashion -WSS

fashion

author：knowledge 2025-08-26 02:42:15 - browse：17316

What happens when an approved drug doesn’t work? Why don’t patients want gene therapy? And is MASH still a big deal?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Bioethicist Holly Fernandez Lynch joins us to discuss the case of Amylyx Pharmaceuticals’ treatment for ALS and what its failure means for drug development. We also discuss the latest news in the life sciences, including a tepid reception for gene therapies, the future of CAR-T cancer treatment, and the first approved medicine for a prevalent liver disease.

For more on what we cover, here’s more on Amylyx; here’s the story on hemophilia gene therapy; here’s the news on Madrigal Pharmaceuticals’ drug for MASH; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

WSS

What AAP's gender

STAT Summit: How researchers deal with rejection

CZI to create biohub to build anti

Is there really a nursing shortage in the U.S.?

Roche drug slashes death risk in early

Readout LOUD podcast: Live from the 2023 STAT Summit

hotspot

fashion

Wikipedia

How one medical school became remarkably diverse

Smaller biotechs seek to piggyback on weight loss drug boom

Psychedelics group wrestles with new pharma identity

How Long Island became the ‘eugenics capital of the world’

Cancer drug shortages should be causing more outrage

Roche acquires Telavant from Roivant, adding experimental IBD treatment

DIEP, the 'gold standard' of breast reconstruction, is under threat

Medicare explains how it will choose drugs for negotiation

Medical records are filled with copy

Feds fine Medicare Advantage plans for overcharging members

knowledge

Roche drug slashes death risk in early

How Long Island became the ‘eugenics capital of the world’

Study on Amgen’s bispecific immunotherapy produces positive data

Winners, losers from Medicare’s list of drugs subject to price talks

UnitedHealth, Optum discontinue NaviHealth name

Roche drug slashes death risk in early

entertainment

Wikipedia

Wikipedia

focus